Dr Joseph A Hill discusses the diagnosis and management of heart failure with preserved ejection fraction (HFpEF).

A recent study finds that much of the cardiovascular disease seen in severely overweight people is driven by more than diabetes and high blood pressure.

Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

View inline View popup Table 1 Demographic and clinical description of patients with heart failure (n=14 670) In our study, almost all patients with HF (98%) suffered from multimorbidity, with an ...

Heart failure is a major health hazard, and millions all over the world are affected by this chronic syndrome each year. Predicting heart failure in patients is extremely tough and inaccurate. To ...

From 1970 to 2022, there was a decrease in heart disease mortality overall, but an increase in mortality from other heart conditions.

While heart failure is fairly common, affecting more than a million people across the UK, many people are unaware of the symptoms to look out for. The condition is also difficult to predict due to its ...

Traditional cardiovascular risk assessment tools underperform among individuals with metabolic dysfunction-associated steatotic liver disease.

Himalayan salt is a pink-colored salt from the mountains of Pakistan. Along with sodium, it contains minerals like calcium, ...

2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association ...

Sacubitril/valsartan treatment is currently indicated in all symptomatic patients with heart failure with an ejection fraction ≤35% already treated with a β-blocker and an ACEi or ARB. 19 However, no ...

As a cardiologist, Dr. Sanjay Bhojraj has treated heart disease for 20 years. If you want your kids to live a long and ...